On the other hand, although the SMARCA4 loss is not directly targetable, Januario and collaborators [60] demonstrated that inhibiting histone methyltransferase EZH2 was effective in SMARCA4-mutated cancer cell lines derived from various tumor types. This evidence concerns the gene PRDM9 and neoplasm.